Showing results (1-10 of 639) with videos related to
Sort By:
Pageof 64
Expert Review of Anticancer Therapy|May 19, 2009
Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasmsEhab Atallah, Srdan VerstovsekExpert Opinion on Emerging Drugs|November 29, 2012
Emerging drugs for myelofibrosisEhab Atallah, Srdan VerstovsekJournal of Hematology & Oncology|August 3, 2012
Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitorsJasleen Randhawa, Alen Ostojic, Radovan Vrhovac, et al.Clinical Advances in Hematology & Oncology : H&O|December 9, 2016
Highlights in polycythemia vera from the 2016 EHA congressSrdan VerstovsekPostgraduate Medicine|February 9, 2013
Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosisSrdan VerstovsekHematology. American Society of Hematology. Education Program|December 17, 2009
Therapeutic potential of JAK2 inhibitorsSrdan VerstovsekAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|January 24, 2014
Therapeutic advances in myeloproliferative neoplasms: the role of new-small molecule inhibitorsSrdan VerstovsekAnnals of Hematology|February 14, 2023
How I manage anemia related to myelofibrosis and its treatment regimensSrdan VerstovsekClinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2010
Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosisSrdan VerstovsekLeukemia Research|November 18, 2008
Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disordersSrdan VerstovsekPageof 64